STUDresearch · Peptide
Teduglutide
Also known as
Gattex · Revestive · GLP-2 analog
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Niche talk
Systemic
Subcutaneous
Gut health
Systemic GLP-2 analog for SBS.
What people say
A prescription GLP-2 analog for adults and certain pediatric patients with short-bowel syndrome who depend on parenteral support. It promotes intestinal adaptation; it is not a fat-loss peptide.
Doses people talk about
This is prescription medical dosing with renal adjustment and monitoring in the full label, not a research-chemical progression.
How it may feel
The clinical goal is reduced parenteral-support dependence over time, not an acute buzz. One first-person report described major symptom improvement plus bloating/gas, with R-CPD as an important competing explanation.
Label-class adult amount0.05 mg/kg SubQ once daily
Weight-based prescription amount in short-bowel syndrome; monitoring and patient-specific adjustments are part of care.
Half-life & effect duration
- Half-life in the body
- Short-bowel syndrome · labelAbout 1.3 hours
- Short-bowel syndrome · population estimateAbout 1.47 hours
- Healthy participantsAbout 2 hours
- Felt duration people report
- One long-term accountOngoing symptom control, with bloating and gas
- After one injectionNo consistent felt window reported
Cycles people discuss
Teduglutide is used as long-term once-daily medical therapy with monitoring, not weeks-on/weeks-off cycling. Fluid and nutrition needs can change when treatment stops.
Timing
The documented clinical treatment is once daily by SubQ injection. The retained record does not establish a preferred morning, evening or meal slot; dosing frequency is distinct from the brief plasma half-life.
Stacks
Clinical nutrition, parenteral support and specialist care are the relevant co-management context. Generic peptide stacks do not establish benefit and can obscure adverse effects.
Watch for
Fluid overload and obstruction monitoring: Increased intestinal absorption can contribute to fluid overload, while intestinal or stomal obstruction is a labeled risk requiring clinical evaluation and possible temporary interruption.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
In adults with short-bowel syndrome, the label reports about 1.3 hours and population PK estimates a typical 1.47-hour plasma half-life.
DailyMed separately reports about 2 hours in healthy participants. The population analysis included 219 short-bowel-syndrome participants and found body weight and renal function influenced exposure.
Population-specific estimates; not a felt-duration measure, not a healthy-volunteer universal and not the time course of intestinal adaptation.
- DailyMed GATTEX (teduglutide) prescribing information (opens in a new tab)Dosage, Warnings and Clinical Pharmacology sections: 0.05 mg/kg once daily SubQ, obstruction/fluid monitoring, and half-life about 2 hours in healthy participants versus 1.3 hours in adults with SBS.Current product label governs approved use but does not predict one person’s subjective sensation or long-term response.
- Population pharmacokinetics of teduglutide in short bowel syndrome (opens in a new tab)Population analysis of 219 participants with SBS and 259 without SBS; typical SBS half-life 1.47 hours, with body weight and renal function affecting exposure and no appreciable accumulation.Model-based population estimate across trials; not a per-injection symptom-duration study.
Felt duration people report
No dependable per-injection felt-duration clock was established.
A first-person author described long-term symptom control and bloating/gas after major bowel resection, but did not report dose-linked onset or offset. Clinical benefit is assessed through ongoing intestinal-support outcomes.
Single uncontrolled account with R-CPD/no-burp symptoms, no dose or dates, and no way to separate disease, anatomy and drug effects.
- A slightly unusual R-CPD story with teduglutide (opens in a new tab)March 2026 first-person post: major bowel resection, teduglutide injection, life-changing symptom control, few negative effects, and bloating/gas alongside longstanding no-burp symptoms.No dose, dates, clinical records or objective outcome; R-CPD and major anatomy changes confound GI sensations.
- Long-term Revestive/Gattex experience request (opens in a new tab)2019 post about recommended daily long-term Revestive for SBS and later 2024–2026 replies from people with historical or newly prescribed exposure.Sparse follow-up, different health systems and little outcome detail; does not establish onset or felt duration.
What people say
- Why it trends: Teduglutide is discussed mainly for gut health-related goals in community and secondary sources. forum
- What people claim: Anecdotes range from subtle to dramatic; lifestyle confounds are the rule. anecdote
- Time course: Early days are often side-effect or placebo window; multi-week blocks are the real checkpoint. forum
- Stack confounding: Multi-agent logs cannot attribute outcomes cleanly to Teduglutide alone. forum
- Parenteral nutrition reduction: Core SBS trial benefit. trial
Doses people talk about
- Not a research-chem fat-loss peptide. forum
- Monitoring: colon polyps/fluid balance monitoring is part of real prescribing. trial
- Label-class: approximately 0.05 mg/kg SC once daily in adult SBS labeling culture. trial
- Framing: GLP-2 analog (Gattex/Revestive) for short bowel — prescription. trial
How it may feel
- Lived experience: A person with major bowel resection said teduglutide improved symptom control with few negative effects but identified bloating and gas; their R-CPD/no-burp symptoms make attribution of those GI sensations uncertain. The post did not provide a dose-linked onset or per-injection duration. anecdote
- Day 1: Most people notice logistics (route, sting, GI) more than a “miracle” effect from Teduglutide. forum
- Days 2–7: Side-effect window for many agents; benefits, if any, are easy to mis-attribute. forum
- Weeks 1–2: First honest checkpoint in self-logs. forum
- Months: Intestinal adaptation endpoints. trial
Cycles people discuss
- No magic cycle: There is rarely one universal “correct” on/off calendar across forums. forum
- Clinical model: Long-term once-daily prescription therapy for short-bowel syndrome, with ongoing monitoring and reassessment; not a bodybuilding or research-chemical cycle. trial
- Reassess: Stop and reassess if adverse effects appear; this is not medical care. forum
- No routine weeks-on/weeks-off cycle: Clinical use is continuous daily treatment when prescribed. Interruptions and discontinuation need medical management because fluid and nutrition requirements can change. trial
Timing
- Timing practicalities: People time doses around side effects, training, and sleep more than perfect PK. Clinical schedule context: The documented clinical treatment is once daily by SubQ injection. The retained record does not establish a preferred morning, evening or meal slot; dosing frequency is distinct from the brief plasma half-life. forumtrial
- Human plasma half-life: DailyMed reports about 2 hours in healthy participants and about 1.3 hours in adults with short-bowel syndrome. A population PK analysis estimated a typical 1.47-hour half-life in short-bowel syndrome. These are body clocks, not the duration of intestinal adaptation. trial
- Published PK: Where human PK exists it should override forum half-life memes for Teduglutide. trial
More on what it is
- Research posture: Educational summary of public discussion and literature themes only. forum
- How people talk about it: Forum volume is a popularity signal for Teduglutide, not proof it works for you. forum
- What it is: GLP-2 analog (Gattex/Revestive) for short bowel syndrome — increases intestinal absorption. trial
- Not a fat-loss GLP-1: Different receptor and indication. trial
- Research only: Not approved advice for self-experimentation; legality and access vary by place. forum
Stacks
- Clinical nutrition care: trial forum
- Less is clearer: Solo runs make personal n=1 easier to interpret than five-compound blasts. forum
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- Injection site (if injected): Redness, itch, lumps, bruise — technique and product quality matter. forum
- Unknowns: Long-term safety for gray-market preparations is often poorly characterized. forum
- Stack noise: Sides logged on multi-agent stacks cannot be blamed cleanly on one compound. forum
- Seek care red flags: Severe allergic reaction, chest pain, neuro changes, or uncontrolled BP/glucose need real medical care — not forum advice. forum
- Gallbladder / GI / neoplastic monitoring themes: Per label warnings. trial
- Fluid overload and obstruction monitoring: Increased intestinal absorption can contribute to fluid overload, while intestinal or stomal obstruction is a labeled risk requiring clinical evaluation and possible temporary interruption. trial
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.